title: Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine.
abstract: Over the past two decades, a host of new molecular pathways have been uncovered that guide mammalian heart development and disease. The ability to genetically manipulate these pathways in vivo have largely been dependent on the generation of genetically engineered mouse model systems or the transfer of exogenous genes in a variety of DNA vectors (plasmid, adenoviral, adeno-associated viruses, antisense oligonucleotides, etc.). Recently, a new approach to manipulate the gene program of the adult mammalian heart has been reported that will quickly allow the high-efficiency expression of virtually any protein in the intact heart of mouse, rat, porcine, nonhuman primate, and human heart cells via the generation of chemically modified mRNA (modRNA). The technology platform has important implications for delineating the specific paracrine cues that drive human cardiogenesis, and the pathways that might trigger heart regeneration via the rapid generation of modRNA libraries of paracrine factors for direct in vivo administration. In addition, the strategy can be extended to a variety of other cardiovascular tissues and solid organs across multiple species, and recent improvements in the core technology have supported moving toward the first human studies of modRNA in the next 2 years. These recent advances are reviewed along with projections of the potential impact of the technology for a host of other biomedical problems in the cardiovascular system.
authors.affiliation: Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138 Department of Cell and Molecular Biology and Medicine, Karolinska Institutet, Stockholm 171 77, Sweden.
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Chien
authors.affiliation: Department of Cardiology, Children's Hospital Boston, Boston, Massachusetts 02115.
authors.forename: Lior
authors.initials: L
authors.lastname: Zangi
authors.affiliation: Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138.
authors.forename: Kathy O
authors.initials: KO
authors.lastname: Lui
mesh_terms: D000818:Animals; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D006321:Heart / Q000502:physiology*; D006331:Heart Diseases / Q000628:therapy*; D006801:Humans; D051379:Mice; D018482:Muscle, Skeletal / Q000502:physiology; D009206:Myocardium / Q000166:cytology; D032383:Myocytes, Cardiac / Q000502:physiology; D019899:Paracrine Communication / Q000502:physiology; D011506:Proteins / Q000378:metabolism; D012333:RNA, Messenger / Q000138:chemical synthesis*; D051381:Rats; D012038:Regeneration / Q000502:physiology; D013234:Stem Cells / Q000502:physiology; D013552:Swine; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D011506:Proteins; D012333:RNA, Messenger; D042461:Vascular Endothelial Growth Factor A